Literature DB >> 25583369

Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature.

Kristyn Deen1, Erin McMeniman.   

Abstract

Erosive genital lichen planus is a disabling, inflammatory mucocutaneous condition that can cause significant patient morbidity and loss of function. Treatment initially involves topical corticosteroids but some patients can have severe treatment-resistant courses requiring systemic immunosuppression. With potentially unfavorable adverse effect profiles and subsequent intolerance of these agents by patients, erosive lichen planus can ultimately be a challenging condition to treat effectively. We present a case of a 66-year-old woman with treatment-resistant erosive genital lichen planus who was successfully managed with mycophenolate mofetil. Although there is only weak evidence for this agent in this condition, its role in dermatology is growing due to its efficacy and advantageous adverse effect profile and should therefore be considered in patients with treatment-resistant erosive genital lichen planus.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  erosive genital lichen planus; lichen planus; mycophenolate mofetil

Mesh:

Substances:

Year:  2015        PMID: 25583369     DOI: 10.1111/1346-8138.12763

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

1.  Lichen planus with multiple system involvement including the mouth, vagina, urethra, and scalp: a case report.

Authors:  Lan Mi; Hong Zhang; Dai Zhang; Miao Zhang
Journal:  Braz J Med Biol Res       Date:  2019-10-10       Impact factor: 2.590

Review 2.  Genital lichen planus: An underrecognized entity.

Authors:  Ananta Khurana; Sidharth Tandon; Yogesh S Marfatia; Nina Madnani
Journal:  Indian J Sex Transm Dis AIDS       Date:  2019 Jul-Dec

3.  Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.

Authors:  Kristin Helene Skullerud; Petter Gjersvik; Are Hugo Pripp; Erik Qvigstad; Anne Lise Ording Helgesen
Journal:  Trials       Date:  2021-07-20       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.